Diane-Isis Nyob: A new video that explains the complex mode of action of our drug for glioblastoma

Diane-Isis Nyob, Senior Market Intelligence Analyst at Debiopharm International SA, recently shared a post by Debiopharm on LinkedIn, adding:

“Honored to share a new video that we elaborated to explain the complex mode of action of our drug for glioblastoma, a devastating brain disease.

This video aims to shed light on our ongoing efforts to fight this aggressive cancer. Thank you for watching and supporting our mission.

At Debiopharm we develop tomorrow’s standards of care to treat cancer and improve patient quality of life”

Quoting Debiopharm’s post:

“Primary brain tumors are notoriously hard to treat due to the lack of treatments that can pass the blood-brain barrier. More brain-penetrant compounds are needed for patients.

As we approach the end of Brain Tumor Awareness Month, our commitment to advancing research and development does not waver. We continue to focus on our investigational program, Debio 0123, a WEE1 inhibitor that is able to overcome one of the most significant challenges in treating brain tumors, crossing the blood-brain barrier.

Discover why this is crucial and how it could change the course of treatment for such a hard-to-treat disease.

Let’s keep spreading knowledge and fostering hope for a future where Glioblastoma can be effectively tackled!”

Read further
Sources: Diane-Isis Nyob/LinkedIn and Debiopharm/LinkedIn